NeurologyLive® Top Stories of 2021: Multiple Sclerosis
These news stories were among the most-discussed conversations in the field and were often included in NeurologyLive®'s coverage in multiple sclerosis.
NeurologyLive® Year in Review 2021: Top Features
As part of NeurologyLive®'s Year in Review, take a look at some of the best features that have been published on the site this year.
This Week on NeurologyLive® — December 27, 2021
Here's what is coming soon to NeurologyLive®.
NeurologyLive® Year in Review 2021: Top Video Interviews
Take a look back at some of the most top video interviews with key experts in neurology and their insights and perspectives on topics in neurology subspecialties, as part of NeurologyLive®'s Year in Review.
NeurologyLive® Friday 5 — December 24, 2021
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 24, 2021.
NeurologyLive® Top Stories of 2021: Epilepsy
These news stories led the pack in conversations in the field of epilepsy and were often included in NeurologyLive®'s coverage of seizure disorders.
NeurologyLive® Top Stories of 2021: Alzheimer Disease & Dementia
These news stories dominated the conversations in the field and were often included in NeurologyLive®'s coverage in Alzheimer disease and dementia.
Novel Oral Treatment Selection in RRMS
Following previous discussions about novel oral therapies available as treatment for relapsing-remitting multiple sclerosis, a small panel of neurologists comment on factors that affect which agent they select.
Purine Antimetabolite Therapy for RRMS
Characteristics that make the purine antimetabolite, cladribine, a unique treatment option for relapsing-remitting multiple sclerosis.
This Week on NeurologyLive® — December 20, 2021
BXCL501 Study in Alzheimer Begins, Ublituximab BLA Accepted, Sublingual Apomorphine Shows Dominance
Neurology News Network for the week ending December 18, 2021. [WATCH TIME: 3 minutes]
NeurologyLive® Friday 5 — December 17, 2021
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 17, 2021.
Pyrimidine Synthesis Inhibitors for RRMS
The advantages of using the pyrimidine synthesis inhibitor teriflunomide to treat relapsing-remitting multiple sclerosis.
S1P Receptor Modulator Treatment Selection in RRMS
Considerations that affect which S1P receptor modulator may be used to treat relapsing-remitting multiple sclerosis, and how to best utilize them during COVID-19.
Building a Discussion Around Genetic Counseling and Testing in ALS
Ellie Harrington, lecturer in genetic counseling, provides answers for patients with ALS who might be unfamiliar with genetic testing and counseling.
This Week on NeurologyLive® — December 13, 2021
Perampanel Improves Comorbid Intellectual Disability, Effects of CBTip in PNES, Cenobamate's Impact in Surgically-Refractory Patients
Neurology News Network for the week ending December 11, 2021. [WATCH TIME: 4 minutes]
NeurologyLive® Friday 5 — December 10, 2021
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 10, 2021.
S1P Receptor Modulators for RRMS
What to know about using S1P receptor modulators as oral therapy for relapsing-remitting multiple sclerosis.
Oral Fumarates for RRMS
Experts discuss types of oral fumarates that are available to treat relapsing-remitting multiple sclerosis, and best practices for selecting an option based on trial data and clinical experience.
This Week on NeurologyLive® — December 6, 2021
Perampanel Improves Comorbid Epilepsy and Migraine, Masupidine to Treat Alzheimer Agitation, Fenfluramine Potential FDA-Approval in LGS
Neurology News Network for the week ending December 4, 2021. [WATCH TIME: 4 minutes]
NeurologyLive® Friday 5 — December 3, 2021
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 3, 2021.
RRMS: Introducing Oral Therapy into Clinical Practice
Considerations that affect recommendations for novel oral treatment for relapsing-remitting multiple sclerosis vs a more conventional option.
Treatment Planning and Shared Decision-Making in RRMS
Best practices for talking about treatment goals and options with patients who have relapsing-remitting multiple sclerosis.
This Week on NeurologyLive® — November 29, 2021
ATH-1017 Phase 2 Completes Enrollment, Heart Rate Variability as SUDEP Biomarker, Migraine Not Associated With Insomnia
Neurology News Network for the week ending November 27, 2021.
NeurologyLive® Friday 5 — November 26, 2021
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 26, 2021.
Early Initiation of Therapy for RRMS
The rationale for early treatment initiation for patients with relapsing-remitting multiple sclerosis.
Appropriate Diagnosis and Management of RRMS
The patient symptoms that help neurologists distinguish relapsing and remitting multiple sclerosis from other forms of the disease, and recommendations regarding the best timing to initiate therapy.